Deadline to Join Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA) is July 14, 2025

If you’re a shareholder of Iovance Biotherapeutics, Inc. (IOVA), you may have the opportunity to participate in a class-action lawsuit. Levi & Korsinsky is currently accepting potential claims against the company, and the deadline for submission is July 14, 2025.

Iovance Biotherapeutics, Inc. is a biotechnology company that focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer. The company’s stock, listed as IOVA, has faced recent challenges that have led to potential legal action. Shareholders who have suffered losses as a result of investing in IOVA may be eligible to join the class-action lawsuit.

Levi & Korsinsky, a national firm with extensive experience in securities litigation, is investigating potential claims against Iovance Biotherapeutics, Inc. The firm is encouraging shareholders who have incurred losses to contact them before the July 14, 2025 deadline to ensure their participation in the class-action lawsuit.

Shareholders who choose to participate in the lawsuit may have the opportunity to recover some of their losses incurred from investing in IOVA. By joining the class action, shareholders can collectively seek justice and hold the company accountable for any alleged misconduct or financial losses.

It’s essential for shareholders to act promptly if they wish to participate in the class-action lawsuit against Iovance Biotherapeutics, Inc. Time is of the essence, as the deadline for submissions is July 14, 2025. Contacting Levi & Korsinsky promptly will ensure that shareholders meet all requirements for inclusion in the legal proceedings.

If you believe you have incurred financial losses as a result of investing in Iovance Biotherapeutics, Inc. (IOVA), now is the time to take action. Contact Levi & Korsinsky to explore your options and potentially join the class-action lawsuit against the company. With the deadline approaching on July 14, 2025, it’s crucial for affected shareholders to act swiftly to secure their position in the legal proceedings.